Gilead-Tubulis $465M ADC Option/License Deal: rNPV Analysis and Milestone Breakdown

On December 3, 2024, Gilead Sciences announced a $465M option and license agreement with Tubulis GmbH for access to the Munich-based biotech's proprietary Tubutecan ADC platform and lead clinical programs. The deal is notable not for its size — it is modest by ADC standards — but for what its structure reveals about how large pharma is recalibrating ADC deal-making after a period of costly clinical setbacks.

For deal teams evaluating ADC partnerships or modeling competitive offers, this transaction provides a case study in risk-managed deal architecture. Below, we dissect the economics, model the option value, and benchmark against the broader ADC deal landscape.

Deal Terms Overview

The Gilead-Tubulis agreement is structured as an option/license arrangement with the following disclosed economics:

The structure is immediately distinctive. A $20M upfront for an ADC platform deal in 2026 is well below the 25th percentile for comparable transactions. Across the 312 ADC transactions in our database since 2018, the median upfront for Phase 1 ADC assets has exceeded $150M in recent quarters. Gilead is paying a fraction of that — and deliberately so.

The Tubulis Platform: Tubutecan and P5 Conjugation

Tubulis has developed two proprietary technologies that underpin its ADC pipeline:

Tubutecan is a novel topoisomerase I inhibitor payload class designed to overcome limitations of existing camptothecin-derived payloads (such as the deruxtecan payload used in Enhertu). The Tubutecan platform aims to deliver improved therapeutic windows — higher efficacy at tolerable doses — particularly in tumors where current ADC payloads face resistance or dose-limiting toxicities.

P5 conjugation technology is Tubulis's proprietary site-specific conjugation platform, which enables homogeneous ADC production with defined drug-to-antibody ratios (DARs). This addresses one of the persistent manufacturing challenges in ADC development: batch-to-batch variability in conjugation efficiency.

The two lead programs in Tubulis's pipeline are:

NaPi2b (sodium-dependent phosphate transporter 2b) is expressed in approximately 80-90% of ovarian cancers and a subset of NSCLC tumors. The target has precedent: AstraZeneca's lifastuzumab vedotin (targeting NaPi2b) was previously evaluated in ovarian cancer, providing clinical validation of the target biology. 5T4 is a tumor-associated antigen expressed across multiple solid tumor types, offering broader indication optionality.

Context: Gilead's Trodelvy Setbacks

The Gilead-Tubulis deal cannot be understood without reference to Gilead's troubled ADC franchise. Trodelvy (sacituzumab govitecan), acquired through the $21B Immunomedics acquisition in 2020, has experienced a series of clinical and commercial setbacks:

1. Bladder cancer withdrawal (2024). Gilead voluntarily withdrew the accelerated approval for Trodelvy in previously treated urothelial carcinoma after the confirmatory TROPiCS-04 trial failed to demonstrate a statistically significant overall survival benefit.
2. NSCLC Phase III failure (2025). The EVOKE-01 trial of Trodelvy in second-line NSCLC failed to meet its primary endpoint of overall survival versus docetaxel, eliminating what would have been a major commercial expansion opportunity.
3. Breast cancer commercial miss. While Trodelvy retains its metastatic triple-negative breast cancer (mTNBC) indication, commercial uptake has been below initial projections, with 2025 net sales of approximately $1.4B — well below the $3B+ peak sales estimates that supported the Immunomedics acquisition price.

These setbacks have fundamentally altered Gilead's approach to ADC investment. Where the Immunomedics deal represented an all-in acquisition bet on a single ADC platform, the Tubulis deal represents the opposite: a capital-efficient option structure that limits downside while preserving upside participation.

rNPV Framework: Modeling the Option Value

The option/license structure of the Gilead-Tubulis deal lends itself naturally to real options analysis. From Gilead's perspective, the $20M upfront is the option premium, the $30M exercise fee is the strike price, and the underlying asset value is the risk-adjusted NPV of the Tubulis pipeline.

Using our rNPV framework, we can model the deal economics under several scenarios:

The asymmetry is striking. Gilead's maximum downside is $20M (the upfront) if both programs fail and the option is never exercised. The upside, if the Tubutecan platform delivers even one approved product in a major solid tumor indication, is measured in hundreds of millions. This is textbook option value — and it explains why Gilead accepted an apparently low total deal value. For a deeper dive into rNPV methodology, see our complete rNPV valuation guide.

Why Option/License Over Acquisition

Given Gilead's market capitalization (~$110B) and balance sheet (~$8B cash), a full acquisition of Tubulis was financially feasible. The decision to structure as an option/license rather than an acquisition reflects three strategic considerations:

1. Capital discipline post-Immunomedics. The $21B Immunomedics acquisition has not delivered expected returns. An option structure allows Gilead to participate in ADC upside without committing acquisition-level capital before clinical proof of concept.
2. Risk management on early-stage assets. TUB-040 is in Phase 1/2a with limited efficacy data. TUB-030 is in Phase 1. Paying acquisition premiums for this stage of clinical development would expose Gilead to binary clinical risk on an underpowered data set.
3. Portfolio optionality. The option structure preserves Gilead's ability to pursue other ADC partnerships or acquisitions simultaneously. An acquisition would have consumed management bandwidth and created integration risk that could delay complementary transactions.

Milestone Waterfall Analysis

The $415M in milestones is structured across development, regulatory, and commercial triggers. Based on analogous ADC option/license deals and typical pharmaceutical milestone allocations, we estimate the following waterfall:

The probability-weighted milestone value of $90-155M, combined with the $20M upfront, gives a risk-adjusted total of $110-175M — which is more in line with current Phase 1 ADC deal benchmarks when accounting for the early stage and option structure. Tubulis has effectively traded a higher upfront for back-loaded milestone payments, accepting more execution risk in exchange for greater total potential value.

ADC Deal Comparison: Benchmarking the Transaction

To contextualize the Gilead-Tubulis deal, we benchmark it against the major ADC transactions since 2020. In our dataset of 2,500+ biopharma transactions, ADC deals have consistently outperformed other modalities on total deal value — and the range of structures illustrates the breadth of valuation approaches in this modality:

The Gilead deal sits at the lower end of ADC deal values, but the comparison is informative. The Pfizer-Seagen and AbbVie-ImmunoGen transactions were acquisitions of companies with approved, revenue-generating products — fundamentally different risk profiles. The Merck-Daiichi and AZ-Daiichi deals involved later-stage assets with substantial clinical data packages. The J&J-Ambrx acquisition, at $2B for a Phase 1 ADC platform, is perhaps the closest comparable — and it highlights how much valuation has shifted toward capital discipline in the 24 months since.

Notably, Tubulis has now executed deals with both BMS ($1B+ option/license in 2025) and Gilead ($465M in 2026), suggesting the company has adopted a strategy of licensing individual programs or targets while retaining platform-level optionality. This is a sophisticated approach that preserves the company's ability to capture full platform value through multiple partnerships rather than a single acquisition event.

Strategic Implications for Deal Teams

The Gilead-Tubulis transaction carries several implications for teams negotiating ADC deals in 2026:

Option/license structures are gaining traction for early-stage ADCs. Based on our tracking of 61 curated comparable deals, option structures now represent 35% of new ADC partnerships — up from 5% in 2023. After several large pharma companies experienced clinical failures on acquired ADC assets (Gilead/Trodelvy, Roche/polatuzumab limitations, various Trop-2 setbacks), the industry is shifting toward structures that limit downside exposure. Deal teams at biotech companies should expect to see more option-based proposals with lower upfronts, and should be prepared to negotiate option exercise timelines, exclusivity terms, and exercise fee economics carefully.

Platform value should be negotiated separately from individual product value. Tubulis has effectively demonstrated this by executing separate deals with BMS and Gilead for different programs while retaining platform ownership. Biotech companies with proprietary ADC platforms should consider multi-partner strategies that maximize total platform value rather than licensing everything to a single acquirer.

Post-failure deal dynamics create opportunity. Gilead's willingness to re-enter the ADC space at a modest price point reflects the commercial imperative of having an ADC franchise, even after setbacks. For biotech companies with differentiated ADC assets, approaching pharma companies that have experienced recent ADC failures may yield faster deal timelines — these companies need to rebuild their ADC portfolios and are often under board-level pressure to do so.

For modeling your own ADC deal terms against current benchmarks, use the Ambrosia deal calculator with the oncology therapeutic area and ADC modality parameters to generate data-driven ranges for upfronts, milestones, and royalties.